Kura oncology, inc. (KURA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating Expenses:
Research and development (includes related party amounts of $132 and $53 for the three months ended March 31, 2020 and 2019, respectively)

47,826

46,787

26,426

16,575

13,905

-

-

-

-

-

Research and development, related party

-

-

-

3,829

3,872

-

-

-

-

-

General and administrative

-

-

-

7,861

6,019

-

-

-

-

-

General and administrative, related party

-

-

-

102

69

-

-

-

-

-

Formation costs

-

-

-

-

-

0

0

0

0

0

General and administrative (includes related party amounts of $111 and $87 for the three months ended March 31, 2020 and 2019, respectively)

19,653

16,096

9,651

-

-

23

22

22

23

20

Total operating expenses

67,479

62,883

36,077

28,367

23,865

-

-

-

-

-

Other Income (Expense):
Management fee income, related party

245

735

780

885

1,200

-

-

-

-

-

Interest income

4,674

3,169

751

499

128

-

-

-

-

-

Operating loss

-

-

-

-

-

-23

-22

-22

-23

-20

Interest expense

580

970

888

577

42

6

5

4

3

1

Loss from extinguishment of debt

-

-498

-

-

-

-

-

-

-

-

Interest expense, related party

-

-

-

-

46

-

-

-

-

-

Total other income

4,339

2,436

643

807

1,240

-

-

-

-

-

Net Loss

-63,140

-60,447

-35,434

-27,560

-22,625

-30

-28

-27

-27

-22

Net loss per share, basic and diluted

-1.51

-1.72

-1.52

-1.47

-2.28

-0.01

-0.01

-0.01

-0.01

0.00

Weighted average number of shares used in computing net loss per share, basic and diluted

41,946

35,191

23,237

18,701

9,933

5,000

5,000

5,000

5,000

-

Comprehensive Loss:
Net loss

-63,140

-60,447

-35,434

-27,560

-22,625

-30

-28

-27

-27

-22

Other comprehensive income:
Unrealized gain (loss) on marketable securities and foreign currency

462

-82

-31

69

-87

-

-

-

-

-

Comprehensive Loss

-62,678

-60,529

-35,465

-27,491

-22,712

-

-

-

-

-

Weighted-average number of common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

5,000